Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

Researchers at Araris Biotech AG have developed antibody-drug conjugate (ADC) technology that allows single-step connection of antibody to drug via a novel RKAA peptide linker that stably prevents the ...

In a busy reporting day for biotechs, Orthocell reports promising results of a follow-up study of its nerve repair device Remplir.

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, ...

Sacituzumab govitecan links an anti-Trop-2 antibody to SN-38, one of the chemotherapy drugs used to kill cancer cells in triple-negative breast cancer [3]. Once the drug binds to the cancer cell ...

A Ludwig Cancer ... anti-tumor immunity in cancer models, even against tumor types that have traditionally resisted checkpoint blockade immunotherapies." The antibody has received "orphan drug ...